At close: 4:10:32 PM GMT+11
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
Cash Flows from Used in Operating Activities Direct
-2,292.8480
-2,292.8480
-1,470.8760
-1,859.1620
Investing Cash Flow
506.5720
506.5720
-557.3880
-115.8940
Financing Cash Flow
818.7050
818.7050
1,997.5580
1,515.5660
End Cash Position
711.9090
711.9090
1,679.4800
1,710.1860
Capital Expenditure
-4.9800
-4.9800
-45.8360
-115.8940
Issuance of Capital Stock
--
--
2,205.0000
1,628.8010
Issuance of Debt
905.0000
905.0000
--
--
Repurchase of Capital Stock
--
--
-137.8500
-103.4620
Free Cash Flow
-2,297.8280
-2,297.8280
-1,516.7120
-1,975.0560
6/30/2022 - 11/25/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NOX.AX Noxopharm Limited
0.1000
+1.01%
SPL.AX Starpharma Holdings Limited
0.1150
0.00%
EZZ.AX EZZ Life Science Holdings Limited
2.6500
+3.52%
BETR.CN BetterLife Pharma Inc.
0.1050
0.00%
BIXT Bioxytran, Inc.
0.0890
+0.45%
RCE.AX Recce Pharmaceuticals Ltd
0.4750
-6.86%
LTP.AX LTR PHARMA FPO [LTP]
0.8950
-3.76%
PAR.AX Paradigm Biopharmaceuticals Limited
0.4200
-5.62%
CU6.AX Clarity Pharmaceuticals Ltd
4.5500
-11.99%
NRX.V NurExone Biologic Inc.
0.7700
0.00%